General Proximity
PrivateLast Round
Early Funding
May 4, 2026
Total Funding Raised
$16M
Company Overview
General Proximity is a biotechnology company that is developing the next generation of induced-proximity medicines. The company's proprietary OmniTAC platform is designed to create treatments for previously "undruggable" proteins associated with conditions like cancer, cardiometabolic disease, neurodegeneration, and longevity. By controlling the proximity of molecules, the company aims to modulate biological processes that were previously beyond the reach of medicine. The company was founded in 2019 and participated in the Y Combinator Winter 2020 batch. General Proximity has raised $16 million in a seed round led by Felicis, with participation from Y Combinator, age1, and others.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
General Proximity Comps
Public and private peers based on sector, stage, and business model.
General Proximity Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 4, 2026 | ||||
| Seed | Jan 3, 2025 |
General Proximity Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| age1 | Seed |
| Y Combinator | Seed |
| Wilson Sonsini Goodrich & Rosati | Seed |
| Healthspan Capital | Seed |
| LifeSpan Vision Ventures | Seed |
| Modi Ventures | Seed |
| Felicis Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2026
Raised capital from Daewoong Pharmaceutical and FreeMind Group.
- Nov 12, 2025
Partnered with Daiichi Sankyo to apply OmniTAC discovery platform to oncology programs.
General Proximity Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about General Proximity's valuation, stock price, and market status.
